Life Sciences News | BioTuesdays by Kilmer Lucas IR

Executive Moves

Joe Dawson joins Rockwell’s BOD

Rockwell Medical (NASDAQ: RMTI) has announced the appointment of Joe Dawson to its board of directors (BOD), and the resignation of Andrea Heslin Smiley from its BOD. Mr. Dawson brings more than 25 years of experience...

November 18, 2025

Developments

HCA HealthONE Rose first in Colorado to adopt Perimeter’s advanced OCT imaging technology for use in surgery

Perimeter Medical Imaging AI (TSXV: PINK; OTCQX: PYNKF) has announced that Dr. Kayla Griffith, Breast Surgical Oncologist, and HCA HealthONE Rose—part of the HCA HealthONE network of 9 hospitals and 17 surgery centers...

November 17, 2025

Developments

Modular receives IRB approval to deliver insulin via Pivot patch pump

Modular Medical (NASDAQ: MODD) has announced that the Institutional Review Board (IRB) has granted approval to conduct an in-house study of its next-generation Pivot insulin delivery system using insulin on people with...

November 17, 2025

Developments

Adaptimmune reports changes to BOD and leadership team

Adaptimmune Therapeutics (OTC PINK: ADAPY) has announced changes to its board of directors (BOD) and leadership team effective November 14, 2025, following the voluntary delisting of the company’s American Depository...

November 17, 2025

Developments

Zynex announces a series of strategic initiatives

Zynex (NASDAQ: ZYXI) has announced the engagement of financial advisory firm Province LLC, the appointment of Paul Aronzon to its board of directors, and the formation of a special committee. Mr. Paul Aronzon brings...

November 14, 2025

Developments

Profound releases record Q3-2025 financial results; says “It’s Happening!”

Profound Medical (NASDAQ: PROF; TSX: PRN) announced that total revenues for the third quarter of 2025 were $5.3 million, representing year-over-year revenue growth of 87%. The gross margin for the third quarter of 2025...

November 13, 2025

Developments

Clearmind expands clinical trial for AUD to Hadassah Medical Center

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that it has received final approval from the Hadassah Medical Center, Jerusalem, Israel, for its ongoing, FDA-regulated Phase 1/2a clinical trial evaluating...

November 13, 2025

Developments

Profound announces distribution agreement with Getz to bring TULSA-PRO to Australia and New Zealand

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has announced that it has entered into an exclusive distribution and supply agreement for its TULSA-PRO system with closely held Getz Healthcare, a leading distributor of...

November 12, 2025

Developments

Profound inks distribution agreement for TULSA-PRO and Sonalleve with Al Faisaliah in Saudi Arabia

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has announced that it has entered into an exclusive distribution and supply agreement for its TULSA-PRO and Sonalleve technologies in Saudi Arabia with Al Faisaliah Medical...

November 11, 2025

Developments

Precision presents late-breaking Phase 1 BDGENE-HBV data at AASLD

Precision BioSciences (NASDAQ: DTIL) announced a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2025, to be delivered by Dr. Man-Fung Yuen, Chair...

November 11, 2025

Executive Moves

Cibus elects Craig Wichner to BOD

Cibus (NASDAQ: CBUS) has announced the election of Craig Wichner to its Board of Directors (BOD) and the board’s strategy committee. “Craig brings an exceptional combination of financial acumen, strategic discipline...

November 11, 2025

Developments

Altimmune’s Phase 2 IMPACT trial data published in The Lancet

Altimmune (NASDAQ: ALT) has announced publication of 4-week efficacy and safety data from the ongoing IMPACT Phase 2b trial of pemvidutide in patients with metabolic dysfunction-associated steatohepatitis (MASH) in The...

November 11, 2025

Subscribe